Ozempic works for weight loss primarily by mimicking a gut hormone called GLP-1 that signals your brain to feel full. It acts on appetite centers in the brain, slows how fast food leaves your stomach, and improves how your body handles blood sugar, all of which contribute to meaningful, sustained weight reduction. In clinical trials, people taking the higher-dose version of semaglutide (the active ingredient in Ozempic) lost roughly 15% of their body weight over about 16 months.
The Brain Signal That Kills Your Appetite
After you eat, your gut releases a hormone called GLP-1 that tells your brain the meal was satisfying. The problem is that natural GLP-1 breaks down within minutes. Semaglutide is a synthetic version engineered to last about a week in your body, keeping that “I’m full” signal turned on far longer than nature intended.
The drug activates GLP-1 receptors in several brain areas that control hunger and reward. The most critical site is a region in the brainstem called the dorsal vagal complex, which processes signals from your gut and plays a central role in suppressing appetite. Semaglutide also reaches parts of the hypothalamus that regulate energy balance. There, it activates neurons that promote fullness while indirectly quieting a separate set of neurons (called AgRP neurons) that normally drive you to seek food. The net effect is that hunger fades and smaller portions feel satisfying.
Beyond simple hunger, semaglutide influences brain areas involved in motivation and reward, including regions associated with cravings and the pleasure response to food. Many people on the drug report that food simply occupies less mental space. The constant background noise of wanting to eat, especially calorie-dense foods, gets turned down. This is not just willpower; it is a pharmacological shift in how the brain prioritizes food.
How It Changes Digestion
Semaglutide slows the rate at which your stomach empties food into the small intestine. In a study of patients undergoing upper endoscopy, 24% of those taking semaglutide had significant residual food in their stomachs, compared with just 5% of people not on the drug. That delayed emptying means you feel physically full for longer after eating, which naturally reduces how much you consume at the next meal.
This same mechanism is responsible for the drug’s most common side effects. Nausea, vomiting, diarrhea, abdominal pain, and constipation each affect more than 5% of users. These symptoms tend to be worst during the early weeks as your body adjusts, which is why the dosing schedule starts low and ramps up gradually.
Effects on Blood Sugar and Fat Storage
Ozempic was originally developed for type 2 diabetes, and its metabolic effects contribute to weight loss even in people without diabetes. When blood sugar rises after a meal, semaglutide prompts your pancreas to release more insulin, the hormone that moves sugar out of your bloodstream and into cells for energy. At the same time, it suppresses glucagon, a hormone that tells the liver to dump stored sugar into the blood. The result is more stable blood sugar with fewer of the sharp spikes and crashes that can trigger hunger and fat storage.
This is glucose-dependent, meaning semaglutide only boosts insulin when blood sugar is actually elevated. That built-in safety feature makes dangerous blood sugar drops uncommon when the drug is used without other diabetes medications.
The Dosing Ramp-Up
Ozempic is a once-weekly injection, and the dose increases in steps to minimize side effects. You start at 0.25 mg per week for the first four weeks, a dose meant purely to let your body acclimate. At week five, the dose rises to 0.5 mg. From there, your prescriber may increase it further based on your response, up to a maximum of 2 mg per week. Most of the meaningful weight loss happens at the higher doses, so the early weeks are about tolerability rather than results.
It is worth noting that Ozempic is FDA-approved specifically for type 2 diabetes. The same molecule, semaglutide, is sold under the brand name Wegovy at higher doses specifically approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. In early 2026, the FDA approved an even higher Wegovy dose of 7.2 mg for additional weight reduction. Many prescribers write Ozempic off-label for weight loss, but the formal weight-loss indication belongs to Wegovy.
Cardiovascular Benefits Beyond Weight Loss
Weight loss alone improves heart health, but semaglutide appears to offer cardiovascular protection that goes beyond what the scale shows. In the SELECT trial, people with pre-existing heart disease and overweight or obesity (but not diabetes) who took semaglutide 2.4 mg weekly had a 20% reduction in major adverse cardiovascular events, including heart attacks, strokes, and cardiovascular death, compared with placebo. This was a significant enough finding that it expanded the medical rationale for prescribing the drug well beyond blood sugar control.
What Happens When You Stop
One of the most important things to understand about Ozempic is that its effects last only as long as you take it. A 2025 systematic review published in The BMJ found that people who stopped semaglutide or similar newer weight-loss medications regained an average of about 9.9 kg (roughly 22 pounds) within the first year after stopping. The rate of regain was approximately 0.8 kg per month, and researchers projected a full return to baseline weight within about a year and a half of discontinuation.
This does not mean the drug “failed.” It means obesity is a chronic condition, and semaglutide treats it the way blood pressure medication treats hypertension: effectively, but only while you take it. The brain’s appetite and reward systems revert once the drug clears, and the biological drive to regain weight reasserts itself. For most people, staying on the medication long-term, or transitioning to sustained lifestyle changes that can partially offset the regain, is part of the realistic plan.
Who Responds Best
Response to semaglutide varies. Some people lose 20% or more of their body weight, while others lose closer to 5%. The reasons for this variability are not fully understood, but factors like starting weight, metabolic health, diet changes made alongside the drug, and individual differences in GLP-1 receptor sensitivity all play a role. People who combine the medication with meaningful dietary and exercise changes tend to see better results than those who rely on the injection alone.
Side effects also vary. Some people tolerate the full dose with minimal nausea, while others struggle with gastrointestinal symptoms throughout treatment. At higher doses, skin sensitivity (described as burning or tenderness, typically at the injection site) has been reported more frequently, though it generally resolves on its own or with a dose reduction.